Table of Contents
Andrew F. Knudten has served as our Senior Vice President, Manufacturing and Supply Chain since September 2015. Previously,
Mr. Knudten served as vice president of operations and vice president of active pharmaceutical ingredient operations at Hospira, Inc. from March 2012 to September 2015, where he had
overall global responsibility for the company's API business. Mr. Knudten also previously served as global head of contract manufacturing and strategy for Novartis Vaccines and
Diagnostics, Inc. from February 2009 to March 2012 and as vice president of manufacturing at CoDa Therapeutics, Inc. from September 2007 to February 2009. From 1994 to 2007, he served in
various research, product development, finance and operations roles at Amgen Inc., supporting the development of numerous pipeline products and more than five eventual commercial products now
being marketed by Amgen. Mr. Knudten earned a B.S. in biology and health from Concordia University, an M.S. in cell biology from University of Nebraska, Lincoln and an M.B.A. from the Anderson
School at the University of California, Los Angeles.
Terrence C. Kearney has served as a member of our board of directors since January
2016. Most recently, Mr. Kearney served as the Chief Operating Officer of Hospira, Inc., a specialty pharmaceutical and medication delivery company, from 2006 until his retirement in
2011. From 2004 to 2006, he served as Hospira's Senior Vice President, Finance, and Chief Financial Officer. He has served as a member of the board of directors of Acceleron Pharma, Inc. since
2014, Vertex Pharmaceuticals Incorporated since 2011 and Innoviva, Inc., formerly known as Theravance, Inc., since 2014. Mr. Kearney received a B.S. in biology from the University of
Illinois and an M.B.A. from the University of Denver. Our board of directors believes that Mr. Kearney should serve as a director based on his extensive experience in the biotechnology industry
as both an executive officer and a director, as well as his financial expertise.
Paul B. Manning has served as a member of our board of directors since April 2014. Mr. Manning is the president and chief
executive officer of PBM Capital Group, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that,
Mr. Manning founded PBM Products, LLC in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of the National
Neurovision Research Institute, the clinical trial support organization of the Foundation Fighting Blindness, and was previously on the board of directors of Perrigo Corporation and Concordia
Healthcare Corp. He is an active member on the UVA Health Foundation Board of Trustees. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our board of directors
believes that Mr. Manning should serve as a director based upon on his over
30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.
Jonathan Leff has served as a member of our board of directors since October 2014. Mr. Leff is a partner of Deerfield Management
Company, LP and chairman of the Deerfield Institute. Prior to joining Deerfield in 2013, Mr. Leff was with Warburg Pincus, LLC for more than 16 years where he led the
firm's investment efforts in biotechnology and pharmaceuticals. Mr. Leff currently serves on the board of directors of the Spinal Muscular Atrophy Foundation, the Biotechnology Industry
Organization, Friends of Cancer Research, and Nivalis Therapeutics, Inc., as well as on the board of advisors of Columbia University Medical Center. Mr. Leff received his A.B. from
Harvard University, and earned his M.B.A. from Stanford University Graduate School of Business. Our board of directors believes Mr. Leff is qualified to serve as a director based upon his
extensive experience in the pharmaceutical and biotechnology industry, including his almost 20 years of experience as a director of multiple public and private biotechnology companies.
Carole Nuechterlein has served as a member of our board of directors since October 2014. Ms. Nuechterlein joined
F. Hoffmann-La Roche Ltd. in 2002 and currently serves as a deputy